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Introduction {#sec1}
============

Hepatitis B and C viruses (HBV and HCV) are the leading causes of chronic liver disease worldwide ([@bib10]). With ∼400 million individuals chronically infected with HBV or HCV and at risk for severe liver disease, these viruses are a major global health burden ([@bib10], [@bib39]). Although HBV and HCV differ in their genomic organization and life cycles, these viruses exclusively infect human hepatocytes ([@bib2]), suggesting that liver-specific factors are important for the life cycle of both viruses.

Viral entry pathways contribute to HBV and HCV liver tropism. HCV requires a number of host proteins, including cluster of differentiation 81 (CD81), scavenger receptor BI (SR-BI), claudin-1 (CLDN1), occludin (OCLN), and accessory factors, such as epidermal growth factor receptor (EGFR), to enter hepatocytes ([@bib2], [@bib18], [@bib19], [@bib46], [@bib48]). Some of these host factors interact directly with HCV glycoproteins, whereas others contribute to HCV internalization by promoting co-receptor associations and inducing intracellular signaling pathways ([@bib14], [@bib18]). While key host factors mediating HCV entry are well characterized ([@bib45]), it is only partially understood how cell entry is regulated. Furthermore, the role of innate immune responses targeting HCV entry is poorly understood.

The sodium taurocholate co-transporting polypeptide (NTCP), a bile acid transporter expressed at the hepatocyte basolateral membrane ([@bib8]), was identified previously as a receptor for HBV and hepatitis D virus (HDV) ([@bib24], [@bib42]). HDV can use HBV envelope proteins to assemble infectious particles and is widely used as a surrogate model to study HBV entry ([@bib35]). Exogenous NTCP expression in NTCP-lacking human hepatoma cell lines (such as Huh7 and HepG2) renders these cells susceptible to HBV/HDV entry ([@bib24], [@bib42]). The natural ligands of NTCP (i.e., conjugated and hydrophilic bile acids) compete with HBV/HDV for NTCP binding and inhibit viral infection ([@bib43]). In contrast, bile acids have been shown to enhance HCV replication ([@bib6], [@bib7]), although the mechanisms are not yet defined. Furthermore, whether bile acid transporters such as NTCP play a role in infection of alternative hepatotropic viruses, such as HCV, is unclear. In this study, we tested the role of NTCP in HCV infection, and we identified the mechanisms by which a solute carrier affects infectivity of three major hepatotropic viruses.

Results {#sec2}
=======

NTCP Overexpression Enhances HCV Infection {#sec2.1}
------------------------------------------

To investigate the effect of NTCP expression on HCV infection, we transduced the Huh7.5.1 cell line ([@bib47]) to express human NTCP. Huh7.5.1-NTCP cells expressed significantly higher NTCP mRNA and protein levels ([Figure 1](#fig1){ref-type="fig"}A) and surface levels of NTCP ([Figure S1](#mmc1){ref-type="supplementary-material"}A) than parental Huh7.5.1 cells. To confirm that NTCP is functional as a viral host factor in these cells, Huh7.5.1-NTCP cells were infected with recombinant HDV. Huh7.5.1-NTCP cells supported HDV infection, as demonstrated by the presence of HDV RNA and delta antigen (HDAg) 7 days post-inoculation ([Figure 1](#fig1){ref-type="fig"}B). Moreover, HDV infection was inhibited by the HBV preS1-derived peptide ([Figure 1](#fig1){ref-type="fig"}B), which binds to NTCP and prevents HBV/HDV entry ([@bib31]).

To assess if NTCP expression affects HCV infection, we used cell culture-derived HCV (HCVcc) and lentiviral particles pseudotyped with HCV E1E2 glycoproteins (HCVpp) of different genotypes. Expression of NTCP significantly enhanced HCVcc (Jc1 and JcR2A) infection and HCVpp (genotypes 1b, 2a, 3a, and 4) entry compared to the parental cells (normalized as 100%) ([Figures 1](#fig1){ref-type="fig"}C and 1D). Interestingly, entry of vesicular stomatitis virus pseudoparticles (VSVpp) and murine leukemia virus pseudoparticles (MLVpp) was not significantly affected by NTCP expression under these conditions ([Figure 1](#fig1){ref-type="fig"}D). The growth of Huh7.5.1 and Huh7.5.1-NTCP cells after seeding was similar, indicating that our observations were unrelated to effects on cell proliferation ([Figure S1](#mmc1){ref-type="supplementary-material"}B). Furthermore, the effect of NTCP on HCV entry/infection was independent of the infectivity levels of different HCVpp and HCVcc strains ([Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D).

Since HCV can infect cells by direct cell-to-cell transmission ([@bib20], [@bib36]), we evaluated the role of NTCP in this mode of viral dissemination. HCV-replicating Huh7.5.1 cells were co-cultured with GFP-expressing Huh7.5 cells ([@bib18], [@bib41]) transduced or not to express NTCP ([Figure 1](#fig1){ref-type="fig"}E). In this assay, the presence of an anti-envelope E2 antibody inhibits cell-free infection, allowing the specific assessment of cell-to-cell transmission. NTCP expression significantly increased the percentage of GFP-positive HCV-infected cells, suggesting that NTCP also plays a role in cell-to-cell spread ([Figures 1](#fig1){ref-type="fig"}F and 1G).

Silencing NTCP Expression Inhibits HCV Infection {#sec2.2}
------------------------------------------------

We confirmed the role of NTCP in HCV infection by silencing NTCP expression in Huh7.5.1-NTCP cells using a small interfering RNA (siRNA) targeting NTCP, prior to infection with HCVcc. Following NTCP silencing in Huh7.5.1-NTCP cells, total protein expression was decreased by ∼80%, which was reflected by decreased surface expression ([Figure 2](#fig2){ref-type="fig"}A). This corresponded to a significant decrease in HCVcc infection ([Figure 2](#fig2){ref-type="fig"}B). To rule out potential off-target effects, we tested multiple NTCP-targeting small hairpin RNA (shRNA) sequences in Huh7.5.1-NTCP cells. We confirmed that a decrease in NTCP expression (by shNTCP2 and shNTCP3) ([Figure 2](#fig2){ref-type="fig"}C) correlated with a decrease in HCVcc infection ([Figure 2](#fig2){ref-type="fig"}D). Furthermore, silencing NTCP expression with shNTCP2 decreased protein expression by \>80% ([Figure 2](#fig2){ref-type="fig"}E), which significantly decreased entry of HCVpp into Huh7.5.1-NTCP cells ([Figure 2](#fig2){ref-type="fig"}F), confirming the relevance of NTCP for HCV entry.

NTCP Modulates HBV/HDV and HCV Infection via Distinct Mechanisms {#sec2.3}
----------------------------------------------------------------

To assess whether NTCP interacts directly with HCV glycoproteins, we measured binding of recombinant soluble HCV E2 (sE2) to cells. We observed no significant difference in sE2 binding to NTCP-expressing or parental cells ([Figure 3](#fig3){ref-type="fig"}A). However, sE2 treatment of Huh7.5.1 cells inhibited HCVcc infection ([Figure 3](#fig3){ref-type="fig"}B), confirming the functionality of the sE2 protein. These findings indicate that NTCP is not involved in E2 binding. Furthermore, NTCP expression did not affect the expression of canonical HCV entry factors in Huh7.5.1-NTCP cells compared to the parental cells ([Figure 3](#fig3){ref-type="fig"}C).

We next tested the effect of the HBV preS1-derived peptide, which is known to bind to NTCP and inhibit HBV/HDV entry ([@bib24]). Although preS1 inhibited HDV infection of Huh7.5.1-NTCP cells after 1 hr pre-treatment, it had no effect on HCVpp entry under these conditions ([Figure 3](#fig3){ref-type="fig"}D), indicating that the HBV preS1-binding domain of NTCP is not required to promote HCV entry. We next evaluated whether the bile acid transporter function of NTCP is important for HCV entry. Huh7.5.1-NTCP cells were treated with the HBV preS1-derived peptide ([@bib15], [@bib32]), which inhibits bile acid uptake in vitro (IC~50~, 4 nM) ([@bib24]), for 24, 48, and 72 hr prior to the addition of HDV, HCVpp, or VSVpp ([Figures 3](#fig3){ref-type="fig"}E--3G). PreS1 treatment (200 nM) significantly inhibited HCVpp entry in a time-dependent manner, with a maximal inhibition of ∼70% after 72 hr ([Figure 3](#fig3){ref-type="fig"}E). Under these conditions, VSVpp entry also was reduced by preS1, although to a lesser extent ([Figure 3](#fig3){ref-type="fig"}F), suggesting a general effect on viral infection. In contrast, HDV infection was impaired by preS1 regardless of the treatment duration ([Figure 3](#fig3){ref-type="fig"}G). HCVcc infection also was decreased by 72-hr preS1 treatment ([Figure 3](#fig3){ref-type="fig"}H), confirming that our observations are relevant for the infectious virus and the full HCV life cycle. Taken together, our data suggest that long-term preS1 inhibition of NTCP-mediated bile acid transport perturbs cellular physiology to modulate HCV entry.

PreS1-Mediated Inhibition of NTCP Induces Interferon-Stimulated Gene Expression {#sec2.4}
-------------------------------------------------------------------------------

Since preS1 only affected HCV entry after long-term treatment ([Figure 3](#fig3){ref-type="fig"}), we hypothesized that the bile acid transport activity of NTCP induces metabolic or transcriptional changes that regulate virus infection. To test this hypothesis, we evaluated the effect of preS1-NTCP binding on gene expression in hepatoma cells. We performed genome-wide microarray analyses of Huh7.5.1-NTCP cells that were treated with preS1 or a scrambled peptide (200 nM) for 48 hr. Gene set enrichment analysis (GSEA) indicated that preS1 treatment induces the expression of genes involved in bile acid and fatty acid metabolism, as previously described ([@bib25]). Unexpectedly, preS1 treatment also induced the expression of genes involved in innate immunity, such as IFNα responses and the Jak/Stat-signaling pathway ([Table 1](#tbl1){ref-type="table"}; [Figure 4](#fig4){ref-type="fig"}A). Interestingly, *IFITM2* and *IFITM3*, which encode two restriction factors targeting HCV entry ([@bib23]), were among the preS1-induced genes ([Figure 4](#fig4){ref-type="fig"}B).

To confirm that IFITMs function as restriction factors in Huh7.5.1-NTCP cells, we exogenously overexpressed IFITM2 and IFITM3 ([Figure 4](#fig4){ref-type="fig"}C). Indeed, IFITM2 and IFITM3 overexpression in Huh7.5.1-NTCP cells inhibited HCVcc infection ([Figure 4](#fig4){ref-type="fig"}D). However, as endogenous *IFITM2* expression in Huh7.5.1 and Huh7.5.1-NTCP cells was low and at the limit of detection, we focused on *IFITM3* in further functional studies. Notably, IFITM3 expression was decreased at the protein level by ∼60% in Huh7.5.1-NTCP cells compared to parental cells ([Figure 4](#fig4){ref-type="fig"}E), suggesting that NTCP modulates *IFITM3* expression. To confirm that the changes in gene expression were directly related to NTCP and not to off-target effects of preS1, we selected *IFITM3* and two other genes involved in IFNα responses (*PARP9* and *CXCL10*) which were induced by preS1 treatment ([Figure 4](#fig4){ref-type="fig"}B), and we compared their expression levels in Huh7.5.1 and Huh7.5.1-NTCP cells. As expected, Huh7.5.1-NTCP cells had decreased mRNA expression of *IFITM3*, *PARP9*, and *CXCL10* compared to parental cells ([Figure 4](#fig4){ref-type="fig"}F), confirming the specific role of NTCP in the suppression of these genes. These data support previous findings that preS1 binds with high specificity to NTCP without off-target effects ([@bib3]).

Bile Acid Transport through NTCP Modulates the Expression of Interferon-Stimulated Genes to Affect HCV Infection {#sec2.5}
----------------------------------------------------------------------------------------------------------------

The gene expression analyses implied that NTCP facilitates HCV entry by altering the expression of interferon-stimulated genes (ISGs). Given that the physiological function of NTCP is to transport bile acids, and bile acids are known to affect ISG expression in hepatocytes ([@bib12], [@bib28]), we hypothesized that bile acid transport by NTCP regulates the expression of ISGs and viral infection. Since IFITM3 functions as an HCV restriction factor in our model system ([Figure 4](#fig4){ref-type="fig"}D), we selected *IFITM3* as a representative ISG for functional studies to probe the link between NTCP and the IFN response. To ensure that IFN responses are indeed functional in Huh7.5.1-NTCP cells, we treated cells with Poly(I:C) and IFNα2, and we evaluated ISG induction by the expression of *IFITM3*. Poly(I:C) stimulation of Huh7.5.1-NTCP cells significantly increased *IFITM3* expression ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Moreover, STAT1 phosphorylation ([Figure S2](#mmc1){ref-type="supplementary-material"}B) and *IFITM3* mRNA expression ([Figure S2](#mmc1){ref-type="supplementary-material"}C) were markedly induced after IFNα2 treatment. This induction was repressed by a specific antibody targeting the type I IFN receptor (IFNAR) ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C).

We then evaluated the effect of NTCP on IFN responses in these cells. The mere presence of NTCP decreased mRNA expression of *IFITM3* by ∼50% compared to parental cells ([Figure 5](#fig5){ref-type="fig"}A). The addition of bile acid (100 μM sodium taurocholate) to Huh7.5.1-NTCP cells decreased *IFITM3* mRNA expression even further, whereas blocking bile acid transport with the preS1 peptide restored *IFITM3* mRNA expression to the levels observed in Huh7.5.1 cells ([Figure 5](#fig5){ref-type="fig"}A). These findings suggest that the effect of NTCP on ISG expression and HCV infection is dependent on bile acid. Indeed, the addition of supplementary bile acid in the cell culture medium dose-dependently increased HCVcc infection in Huh7.5.1-NTCP cells, but not in parental cells ([Figure 5](#fig5){ref-type="fig"}B).

We next evaluated the effect of preS1 treatment on IFITM3 protein expression and HCV infection in the presence of bile acids. Reflecting our observations of the mRNA level ([Figure 5](#fig5){ref-type="fig"}A), IFITM3 protein expression was decreased in Huh7.5.1-NTCP cells compared to Huh7.5.1 cells in the presence of bile acid ([Figure 5](#fig5){ref-type="fig"}C). However, treatment of Huh7.5.1-NTCP cells with preS1 (to block bile acid uptake) under these conditions induced a 2-fold increase in IFITM3 protein expression, effectively restoring it to the level observed in Huh7.5.1 cells ([Figure 5](#fig5){ref-type="fig"}C). Furthermore, treatment of Huh7.5.1-NTCP cells with the preS1 peptide in the presence of bile acid inhibited HCVcc infection ([Figure 5](#fig5){ref-type="fig"}D). We did not observe these effects in Huh7.5.1 cells ([Figures 5](#fig5){ref-type="fig"}C and 5D), confirming that the bile acid-mediated effect is dependent on NTCP.

Interestingly, when we silenced *IFITM3* expression ([Figure 5](#fig5){ref-type="fig"}E) in the presence of bile acid, we observed an increase in HCV infection ([Figure 5](#fig5){ref-type="fig"}F). However, this effect was no longer observed in the presence of preS1 to block bile acid uptake into the cells or in the absence of bile acid ([Figure 5](#fig5){ref-type="fig"}F). These results suggest that bile acid-mediated suppression of other ISGs (which may otherwise compensate the absence of an individual ISG) is necessary to observe a functional effect of *IFITM3* silencing on HCV infection. Differences in bile acid levels in cell culture medium also may explain why IFITM3 was not identified as an HCV restriction factor in previous screens ([@bib4]).

NTCP-Mediated Bile Acid Transport Affects ISG Expression and HCV Entry into Primary Human Hepatocytes {#sec2.6}
-----------------------------------------------------------------------------------------------------

For validation in a more physiological context, we investigated the role of NTCP during HCV entry into primary human hepatocytes (PHHs). First, we silenced NTCP expression in PHHs using an NTCP-targeting siRNA. Following transfection of siNTCP, the expression of NTCP protein was reduced by ∼50% ([Figure 6](#fig6){ref-type="fig"}A). The decrease in NTCP expression correlated with a significant decrease in the entry of HCVpp genotype 1b ([Figure 6](#fig6){ref-type="fig"}B).

We next evaluated whether NTCP-mediated bile acid transport affects ISG expression in PHHs. We treated PHHs with bile acid in the presence or absence of preS1 and performed genome-wide microarray analyses. GSEA showed that bile acid treatment of PHHs suppressed the expression of genes involved in the IFNα response (normalized enrichment score \[NES\] −2.11; p value \< 0.001; false discovery rate \[FDR\] \< 0.001) ([Figure 6](#fig6){ref-type="fig"}C) as well as other immune-related pathways. However, treatment of PHHs with preS1 under these conditions induced the expression of genes involved in the IFNα response (NES 1.5; p value = 0.014; FDR = 0.035) to restore their expression levels to normal conditions (i.e., PHHs in the absence of bile acid) ([Figure 6](#fig6){ref-type="fig"}D). These findings are consistent with our microarray analyses in Huh7.5.1-NTCP cells ([Figure 4](#fig4){ref-type="fig"}), where expression of genes involved in IFNα responses was regulated by treatment with preS1. Interestingly, *IFITM1*, *IFITM2*, and *IFITM3* were among the genes suppressed by bile acid treatment of PHHs ([Figure 6](#fig6){ref-type="fig"}C), and their expression could be rescued by the addition of preS1 ([Figure 6](#fig6){ref-type="fig"}D). Moreover, the effects we observed in PHHs were dependent on the presence of bile acid, as treatment with preS1 in the absence of bile acid did not have a major impact on the expression of these genes (data not shown).

We next evaluated the functional effect of these changes in ISG expression on HCVpp entry into PHHs. Treatment of PHHs with bile acid increased HCVpp genotype 1b entry, and the addition of preS1 under these conditions restored the level of infection to that observed in the absence of bile acid ([Figure 6](#fig6){ref-type="fig"}E). Interestingly, the concentration of bile acid required to see a robust effect for HCVpp entry into PHHs was higher than for HCVcc infection of Huh7.5.1-NTCP cells ([Figure 5](#fig5){ref-type="fig"}B), which may reflect different bile acid uptake efficiency in PHHs or that the effect is more potent when the full HCV life cycle is measured and ISGs targeting different steps of the viral infection cycle are involved. Finally, to confirm that the activity of preS1 is linked to IFN responses, we tested the effect of preS1 in the presence of an antibody blocking the type I IFN receptor. In the presence of this antibody, preS1 no longer inhibited HCVpp entry into PHHs ([Figure 6](#fig6){ref-type="fig"}F), suggesting that the inhibitory effect of preS1 against HCV entry is indeed mediated by the IFN signal transduction cascade and resulting IFN responses in PHHs.

Discussion {#sec3}
==========

NTCP was recently described as a major receptor for HBV and HDV entry. Here we show that NTCP also plays a role in HCV infection. Exogenous expression of NTCP in Huh7.5.1 hepatoma cells increased HCV infection, whereas silencing of NTCP expression reduced HCV entry ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Using microarray analyses in cell lines ([Figure 4](#fig4){ref-type="fig"}) and PHHs ([Figure 6](#fig6){ref-type="fig"}), we discovered that NTCP-mediated bile acid transport regulates innate antiviral responses, thereby inhibiting HCV infection and uncovering a role for NTCP as a regulator of antiviral immunity.

Innate antiviral responses mediated by ISGs have been shown to target multiple steps during viral infection, including entry ([@bib17], [@bib33]). IFITM1, IFITM2, and IFITM3, which belong to a group of five IFN-induced transmembrane proteins ([@bib33]), have been shown to exert broad antiviral activity against a range of viruses, including VSV, HIV, dengue virus, influenza virus, and Zika virus ([@bib29], [@bib33]). Interestingly, IFITM2 and IFITM3 were recently reported to restrict HCV infection at a late entry step by targeting HCV for lysosomal degradation following endocytosis ([@bib23]). IFITM1 was shown to interact with HCV co-receptors at tight junctions to disrupt the HCV entry process by alternative mechanisms ([@bib40]).

Given that bile acids have been shown to modulate cellular antiviral responses ([@bib12], [@bib28]), we hypothesized that NTCP affects the induction of ISG expression via its bile acid transport activity. Indeed, the expression of ISGs (including *IFITM1*, *IFITM2*, and *IFITM3*) in PHHs was suppressed by the addition of bile acid ([Figure 6](#fig6){ref-type="fig"}C). However, expression of these ISGs in PHHs was restored by addition of the preS1 peptide, which blocks NTCP-mediated bile acid uptake ([Figure 6](#fig6){ref-type="fig"}D). Furthermore, modulation of the expression of IFITM3 by bile acid or preS1 treatment had a clear functional effect on HCV infection ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). Our findings are consistent with a previous report showing that bile acids affect HCV replication ([@bib7]), probably by similar mechanisms as those we describe here. In this study, we selected *IFITM3* as a representative ISG for functional characterization, but the expression of other ISGs is also affected by bile acids ([Figure 6](#fig6){ref-type="fig"}), likely contributing further to the overall effect on HCV infection. Since ISGs broadly restrict viral infection, this is consistent with the time-dependent effect of preS1 on VSVpp entry that we observed ([Figure 3](#fig3){ref-type="fig"}).

Our data suggest that NTCP facilitates HCV infection by modulating bile acid transport and ISG expression. ISGs also restrict HCV cell-to-cell transmission ([@bib21]), consistent with our finding that NTCP contributes to HCV cell-to-cell spread ([Figures 1](#fig1){ref-type="fig"}E--1G). It should be noted that NTCP expression did not appear to affect HCV entry in a recent Huh7 cell line model ([@bib22]). Huh7.5.1 cells are derived from Huh7.5 cells, which differ from Huh7 cells by a single point mutation in the retinoic acid-inducible gene-I ([@bib1], [@bib47]). This may explain the differences observed between the two cell lines. Moreover, differences in bile acid concentrations in cell culture medium may be responsible for differences in the effect of NTCP on cell entry of HCV ([Figure 5](#fig5){ref-type="fig"}C). However, our loss-of-function studies and microarray analyses in PHHs ([Figure 6](#fig6){ref-type="fig"}) clearly demonstrate the impact of NTCP on HCV infection in primary cells with physiological innate immune responses.

For HBV/HDV infection, viral entry requires direct interaction with NTCP ([@bib24], [@bib42]). Furthermore, HBV binding to NTCP may interfere with the physiological function of NTCP (i.e., bile acid uptake), and NTCP ligands can abrogate HBV/HDV infection ([@bib25], [@bib43]). In contrast, NTCP modulates HCV entry independently of direct binding mechanisms. We confirmed the inhibitory effect of the HBV preS1-derived peptide on HDV infection following 1-hr treatment ([Figure 3](#fig3){ref-type="fig"}D), but we did not see a corresponding effect on HCV infection under these conditions. Furthermore, the effect of NTCP on HCV infection does not appear to involve HCV E2 or binding factors CD81 and SR-BI ([@bib27], [@bib30]) ([Figures 3](#fig3){ref-type="fig"}A and 3B). NTCP expression did not modulate the expression of canonical entry factors CLDN1 and OCLN or EGFR either ([Figure 3](#fig3){ref-type="fig"}C).

Other mechanisms may contribute to the effects of NTCP on viral entry and infection that we observed. Indeed, modulation of NTCP bile acid transport activity by preS1 affected IFN responses, but also bile acid metabolism and cholesterol homeostasis in Huh7.5.1-NTCP cells as well as other pathways ([Table 1](#tbl1){ref-type="table"}). In particular, modulation of bile acid metabolism and cholesterol homeostasis by preS1 would alter cellular cholesterol pools, which has been shown to affect the activation of type I IFN responses ([@bib44]) and may potentially contribute to the effect on HCV infection that we observed. Furthermore, modulation of signaling and transcription factor targets ([Table 1](#tbl1){ref-type="table"}) may have additional effects on viral replication and translation.

Our results demonstrate that NTCP, acting by distinct mechanisms, is relevant for the three major viruses causing chronic hepatitis and liver disease. This finding could contribute to the development of antiviral strategies targeting NTCP. Targeting viral cell entry with receptor antagonists, antibodies, peptides, and receptor kinase inhibitors has provided perspectives to prevent and treat chronic hepatitis B and C infections ([@bib9]). Myrcludex B, a preS1-derived peptide targeting NTCP ([@bib24], [@bib38]), has been shown to protect against HBV infection ([@bib26]), to modulate viral spread in animal models ([@bib38]), and to decrease HDV viral load in patients in a phase II clinical trial ([@bib3]). Here we show that preS1-NTCP binding enhances the expression of ISGs. These data suggest that myrcludex B may inhibit HBV infection by a dual mode of action, by interfering with viral binding and potentially increasing ISG expression. NTCP-targeting agents in clinical development also may inhibit HCV infection, which is of interest particularly for patients with HBV/HDV/HCV co-infections.

NTCP is a member of the solute carrier (SLC) family of proteins, a group of membrane proteins having crucial roles in many physiological functions ([@bib5]). However, these proteins are relatively uncharacterized. Here we uncover NTCP as a mediator of innate antiviral responses in hepatocytes and establish a role for NTCP in the entry process of multiple viruses. Our data uncover an important role of SLCs in virus-host interactions by linking their function to the regulation of innate immune responses. Moreover, bile acid transport through SLCs profoundly affects liver gene expression ([Table 1](#tbl1){ref-type="table"}).

Overall, we have identified NTCP as a regulator of innate immune responses in the human liver. These findings improve the understanding of virus-host interactions in the human liver, and they may open perspectives for the development of broad antiviral therapies targeting hepatotropic viruses that cause chronic liver disease and cancer.

Experimental Procedures {#sec4}
=======================

Cell Lines {#sec4.1}
----------

The sources for 293T and Huh7.5.1 cells have been described ([@bib18]). Huh7.5.1 cells were seeded in six-well plates at 50% confluency 1 day prior to transduction with human NTCP-expressing VSVpp (GeneCopoeia). Cells were incubated in DMEM (Gibco) containing 10% fetal bovine serum (Dutscher). After 3 days, the cells were expanded and selected for NTCP expression with 1.8 μg/mL puromycin.

PHHs {#sec4.2}
----

Liver tissue from patients undergoing surgical resection was obtained with informed consent from all patients. The respective protocols were approved by the Ethics Committee of the University of Strasbourg Hospitals (CPP 10-17). PHHs were isolated from liver resection tissue and cultured in William's E medium (Sigma) ([@bib16], [@bib18]).

Viral Infection {#sec4.3}
---------------

Lentiviral pseudoparticles expressing HCV envelope glycoproteins (HCVpp strains HCV-J \[1b\], JFH1 \[2a\], NIH S52 \[3a\], and UKN4.21.16 \[4\]), VSVpp, MLVpp, as well as cell culture-derived HCVcc (Luc-Jc1 and Luc-JcR2A) were generated as described ([@bib11], [@bib18]). Huh7.5.1 cells and PHHs were infected as described ([@bib16], [@bib18]). Pseudoparticle entry and HCVcc infection were assessed by measuring luciferase activity 72 hr post-infection ([@bib16], [@bib18]). HDV production and infection have been described ([@bib37]) (see the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).

Gene Expression Analyses in Huh7.5.1-NTCP Cells and PHHs Treated with Bile Acids and preS1 Peptide {#sec4.4}
--------------------------------------------------------------------------------------------------

Huh7.5.1-NTCP cells were treated with preS1 or a control peptide (200 nM) for 48 hr. Alternatively, PHHs were treated with bile acids (500 μM) in presence of preS1 or a control peptide (400 nM) for 48 hr. Total RNA from three biological replicates per condition from one experiment was then extracted using the ReliaPrep Kit (Promega), and 200 ng was subjected to genome-wide transcriptome profiling using HumanHT-12 beadarray (Illumina), following the manufacturer's protocol. Raw scanned data were normalized by cubic spline algorithm using Illumina normalizer module of GenePattern genomic analysis toolkit (<http://software.broadinstitute.org/cancer/software/genepattern>), as previously described ([@bib13]). Modulated molecular pathways were determined using GSEA ([@bib34]).

Statistical Analysis {#sec4.5}
--------------------

Each experiment was performed at least two times in an independent manner. The number of independent experiments as well as the total number of biological replicates (n) are indicated in the figure legends. Statistical analyses were performed using Mann-Whitney U test by comparing values from every biological replicate per study (indicated by "n" in the figure legends); p \< 0.05 (^∗^), p \< 0.01 (^∗∗^), and p \< 0.001 (^∗∗∗^) were considered statistically significant. Significant p values are indicated by asterisks in the individual figures. For microarray analyses, two-tailed unpaired Student's t test was performed by comparing the values from three biological replicates (p \< 0.05 was considered statistically significant).
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![NTCP Expression Modulates HCV Infection\
(A) NTCP expression in Huh7.5.1-NTCP cells compared to parental Huh7.5.1 cells evaluated by qRT-PCR and western blot. qRT-PCR results are expressed as means ± SD. NTCP expression was normalized by GAPDH expression (log) from three independent experiments performed in triplicate (n = 9).\
(B) Functional evaluation of HDV infection in Huh7.5.1-NTCP cells using northern blot and immunofluorescence (IF). Huh7.5.1 and Huh7.5.1-NTCP cells were treated with an HBV-derived preS1 peptide (PreS1) or with a control peptide (Ctrl) (200 nM) and infected with recombinant HDV for 7 days. HDV RNA was detected by northern blot. HDV+ corresponds to ∼2 × 10^7^ HDV RNA genome equivalents extracted from HDV particles produced in Huh7 cells. NI, non-infected cells. One experiment is shown. For IF analysis, cells were fixed 7 days after infection and stained with HDAg-specific antibodies purified from HBV/HDV co-infected patients. HDV-positive cells are visualized in red. Cell nuclei were stained with DAPI (blue). One experiment is shown.\
(C and D) HCVcc and HCVpp infection of NTCP-overexpressing cells. Huh7.5.1 and Huh7.5.1-NTCP cells were infected with HCVcc (C, Luc-Jc1 and Luc-JcR2A; D, HCVpp (genotypes 1b, 2a, 3a, and 4), VSVpp, and MLVpp). Infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SEM percentage virus infection relative to parental Huh7.5.1 cells from three independent experiments (one performed in triplicate, one in quintuplicate, and one in hextuplicate; n = 14) (C) or three independent experiments performed in triplicate (n = 9, except MLVpp: two independent experiments performed in triplicate, n = 6).\
(E--G) NTCP overexpression increases HCV cell-to-cell transmission. HCV-electroporated Huh7.5.1 were transduced or not (Ctrl) with lentiviruses expressing NTCP. (E) NTCP expression was assessed by qRT-PCR. Results are expressed as means ± SD relative NTCP expression (log) compared to NTCP expression in non-transduced cells (set at 1) from one experiment performed in triplicate (n = 3). Cells were then co-cultured with GFP-expressing Huh7.5.1 cells in the presence of neutralizing antibody AP33. (F and G) After NS5A staining, HCV cell-to-cell transmission was assessed by flow cytometry as the percentage of GFP- and NS5A-positive cells. One experiment is shown (F) and results are expressed as means ± SD percentage infected cells from two independent experiments (one performed in hextuplicate and one in nonuplicate; n = 15) (G).](gr1){#fig1}

![Silencing NTCP Expression Inhibits HCV Infection in Human Hepatocytes\
(A and B) NTCP silencing in hepatoma cell lines. Huh7.5.1-NTCP cells were transfected with siRNA control (siCtrl) or siRNA targeting NTCP (siNTCP). siRNA efficacy was assessed 72 hr after transfection by western blot and IF (scale bar, 10 μm) (A), and cell viability was assessed using PrestoBlue reagent (B). 3 days after NTCP silencing, Huh7.5.1-NTCP cells were infected with HCVcc (Luc-Jc1). Infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SEM percentage cell viability compared to cells treated with siCtrl from three independent experiments (one performed in sextuplicate and two performed in octuplicate; n = 22) and means ± SEM percentage HCVcc infection from four independent experiments performed in quadruplicate (n = 16) (B).\
(C--F) Effect of shNTCP silencing in hepatoma cells. Huh7.5.1-NTCP cells were transduced with lentiviruses expressing shRNAs targeting NTCP (shNTCP1, shNTCP2, or shNTCP3) or control shRNA (shCtrl). shRNA efficacy was assessed 72 hr after transduction by western blot (C) or by western blot and IF (scale bar, 10 μm) (E). Cell viability was assessed using PrestoBlue reagent (D). Results are expressed as means ± SEM percentage cell viability from three independent experiments performed in octuplicate (n = 24). 3 days after NTCP silencing, Huh7.5.1-NTCP cells were infected with HCVcc (Luc-Jc1) (D and F), HCVpp (genotype 1b) (F), or VSVpp (F). Infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SEM percentage HCVcc infection from three independent experiments (two performed in quadruplicate and one in sextuplicate; n = 14) (D), or they are expressed as means ± SEM percentage pseudoparticle entry from three independent experiments performed in triplicate (n = 9) (F) and as means ± SEM percentage HCVcc infection from three independent experiments performed in quadruplicate (n = 12) (F).](gr2){#fig2}

![Distinct Roles of NTCP in HDV/HBV and HCV Infections\
(A) Flow cytometry analysis of HCV glycoprotein sE2 binding to Huh7.5.1 (Ctrl) and Huh7.5.1-NTCP (NTCP). Results are expressed as means ± SD percentage sE2 binding compared to control cells from three independent experiments (two performed in triplicate and one in quadruplicate; n = 10).\
(B) sE2 binding inhibits HCVcc infection. Huh7.5.1 cells were treated with soluble sE2 and then infected with HCVcc (Luc-Jc1). Infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SD percentage HCVcc infection from three independent experiments performed in triplicate (n = 9).\
(C) Flow cytometry analysis of HCV entry factor expression in Huh7.5.1-NTCP cells. Results are expressed as percentage protein expression compared to parental Huh7.5.1 cells (set at 100%) from four independent experiments performed in duplicate (n = 8).\
(D) Effect of HBV preS1-derived peptide on HDV, HCVpp (genotype 1b), and VSVpp entry into Huh7.5.1-NTCP cells. Huh7.5.1-NTCP cells were treated for 1 hr with preS1 or Ctrl peptide (200 nM). For HDV, cells were then infected with recombinant HDV for 7 days. Total RNA was purified and HDV RNA was detected by qRT-PCR. Results are expressed as percentage HDV RNA level compared to non-treated Huh7.5.1-NTCP cells from three independent experiments performed in triplicate (n = 9). For HCVpp (genotype 1b) and VSVpp, cells were infected with pseudoparticles and infection was assessed after 72 hr by luciferase activity. Results are expressed as means ± SD percentage viral entry from three independent experiments performed in quintuplicate (n = 15).\
(E--G) Time-dependent inhibition of viral entry by preS1 treatment. Cells were treated with preS1 or Ctrl peptide for 24, 48, and 72 hr prior to infection with HCVpp (genotype 1b), VSVpp, or HDV. Infection was assessed as described above. (E) Results are expressed as means ± SD percentage HCVpp entry from five independent experiments performed in triplicate (n = 15). (F) Results are expressed as means ± SD percentage VSVpp entry from four independent experiments performed in triplicate (n = 12). (G) Results are expressed as means ± SD percentage HDV infection from three independent experiments performed in duplicate (n = 6).\
(H) Treatment with preS1 inhibits HCVcc infection. Cells were treated with preS1 or Ctrl peptide for 72 hr prior to infection with HCVcc (Luc-Jc1). Infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SD HCVcc infection (relative light unit, RLU) from three independent experiments performed in triplicate (n = 9).](gr3){#fig3}

![Binding of HBV-Derived preS1 Peptide to NTCP Increases ISG Expression\
Huh7.5.1-NTCP cells were treated with preS1 or control peptide for 48 hr. Cells were then lysed and total RNA was extracted and purified. Total gene expression was analyzed by genome-wide microarray. Three independent biological replicates per condition from one experiment were analyzed.\
(A) Schematic representation of Hallmark gene sets that are significantly induced (red, including bile acid metabolism and IFNα response) or repressed (blue) following preS1 treatment, based on [Table 1](#tbl1){ref-type="table"}. p \< 0.05 and FDR \< 0.05 were considered statistically significant.\
(B) List of individual IFNα response genes that are significantly (p \< 0.05) overexpressed following preS1 treatment. Individual *Z* scores for each sample are presented. Negative *Z* score (blue) and positive *Z* score (red) correspond to repression and induction of the indicated genes, respectively.\
(C and D) IFITM2 and IFITM3 overexpression inhibits HCV infection. Huh7.5.1-NTCP cells were transfected with an empty vector, pCMV-HA-hIFITM2, or pCMV-HA-hIFITM3 for 3 days. (C) Expression of transduced proteins as assessed by anti-HA western blot is shown. (D) Transduced cells were then infected for 3 days with HCVcc (Luc-Jc1). Infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SD percentage HCVcc infection compared to control cells (set at 100%) from three independent experiments performed in triplicate (n = 9).\
(E) IFITM3 protein expression in hepatoma cells. IFITM3 protein expression was assessed by western blot in Huh7.5.1 and Huh7.5.1-NTCP cells. One experiment is shown.\
(F) *IFITM3*, *PARP9*, and *CXCL10* expression in hepatoma cells. Basal expression of *IFITM3*, *PARP9*, and *CXCL10* mRNA was quantified by qRT-PCR in Huh7.5.1 and Huh7.5.1-NTCP cells. Results are expressed as means ± SD percentage gene expression compared to expression levels in Huh7.5.1 cells (set at 100%) from three independent experiments performed in triplicate (n = 9).](gr4){#fig4}

![Bile Acid Uptake Enhances HCV Infection by Decreasing ISG Expression\
(A) The impact of bile acid and preS1 treatment on *IFITM3* expression. Huh7.5.1-NTCP cells were treated with the bile acid (BA) sodium taurocholate (100 μM) or with 200 nM preS1 for 72 hr. IFITM3 expression was then quantified by qRT-PCR. Results are expressed as means ± SD percentage IFITM3 expression compared to untreated (Ctrl) Huh7.5.1-NTCP cells (set at 100%) from three independent experiments performed in duplicate (n = 6).\
(B) The impact of bile acid on HCVcc infection. Huh7.5.1 and Huh7.5.1-NTCP cells were treated 0, 25, or 100 μM sodium taurocholate for 72 hr and then infected with HCVcc (Luc-Jc1). Results are expressed as means ± SD percentage HCVcc infection compared to untreated (Ctrl) Huh7.5.1 and Huh7.5.1-NTCP cells (both set at 100%) from three independent experiments performed in triplicate (n = 9).\
(C and D) Effect of preS1-mediated inhibition of bile acid uptake on IFITM3 protein expression and HCVcc infection. Huh7.5.1 and Huh7.5.1-NTCP cells were treated with sodium taurocholate (100 μM) in the presence or absence of preS1 peptide for 72 hr. (C) IFITM3 protein expression was assessed by western blot. One experiment is shown. (D) Cells were then infected by HCVcc (Jc1) for 3 days. Results are expressed as means ± SD percentage HCVcc infection compared to Huh7.5.1 and Huh7.5.1-NTCP cells treated with control peptide (both set at 100%) from three independent experiments performed in triplicate (n = 9).\
(E and F) Silencing of *IFITM3* expression increases HCV infection in a bile acid-dependent manner. Huh7.5.1-NTCP cells were transfected with siRNA control (siCtrl) or siRNA targeting IFITM3 (siIFITM3) and then treated for 72 hr in the absence or presence of BA (100 μM) in the presence of either preS1 or Ctrl peptide (200 nM). (E) Then 3 days after transfection, silencing efficacy was assessed by measuring expression of *IFITM3* mRNA by qRT-PCR. Results are expressed as means ± SD percentage *IFITM* expression from four independent experiments performed in triplicate (n = 12). (F) Cells were then infected with HCVcc Luc-Jc1. Infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SD percentage HCVcc infection compared to cells treated with siCtrl (set at 100% for each condition) from four independent experiments performed in triplicate (n = 12).](gr5){#fig5}

![NTCP-Mediated Bile Acid Uptake Modulates ISG Expression and HCV Entry in PHHs\
(A and B) Silencing NTCP expression in PHHs. PHHs were transfected with siRNA control (siCtrl) or siRNA targeting NTCP (siNTCP). 3 days after transfection, siRNA efficacy was assessed by western blot (A), and cell viability was assessed using PrestoBlue reagent (B). Results are expressed as means ± SEM percentage cell viability compared to cells treated with siCtrl from two independent experiments performed in quintuplicate (n = 10) (B). 3 days after NTCP silencing, PHHs were incubated with HCVpp (genotype 1b). Infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SEM percentage HCVpp entry from three independent experiments performed in triplicate (n = 9) (B).\
(C and D) Bile acids modulate the expression of ISGs in PHHs. PHHs from a single donor were treated with the bile acid (BA) sodium taurocholate (500 μM) in the presence or absence of the preS1 peptide (400 nM) for 48 hr. Cells were then lysed and total RNA was extracted and purified. Total gene expression was analyzed by genome-wide microarray. Three independent biological replicates per condition were analyzed. (C) Individual IFNα response genes that are significantly (p \< 0.05) repressed following BA treatment are shown. Individual *Z* scores for each sample are presented. Negative *Z* score (blue) and positive *Z* score (red) correspond to repression and induction of the indicated genes, respectively. (D) Effect of preS1 treatment on the expression of IFNα response genes presented in (C). Individual *Z* scores for each sample are presented.\
(E) Effect of bile acid and preS1 treatment on HCVpp infection in PHHs. PHHs were treated with increasing concentrations (0, 100, and 500 μM) of BA in the presence of either preS1 or Ctrl peptide (400 nM) for 72 hr and then infected with HCVpp (genotype 1b). Infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SEM percentage HCVpp entry compared to untreated PHHs in the presence of the control peptide (set at 100%) from four independent experiments performed in triplicate (n = 12).\
(F) PreS1 inhibition of HCVpp entry is dependent on the IFN-signaling pathway in PHHs. PHHs were treated with 500 μM BA in the presence of preS1 or a scrambled control peptide (400 nM), with or without treatment with an antibody targeting the type I IFN receptor (IFNAR) for 72 hr. Cells were then infected with HCVpp (genotype 1b) and infection was assessed after 72 hr by measuring luciferase activity. Results are expressed as means ± SEM percentage HCVpp entry compared to PHHs treated with the control peptide and an IgG control (set at 100%) from three independent experiments (one performed in triplicate and two in quintuplicate; n = 13).](gr6){#fig6}

###### 

Hallmark Gene Sets Significantly Induced, Positive NES[a](#tblfn1){ref-type="table-fn"}, or Repressed, Negative NES, after preS1 Treatment in Huh7.5.1-NTCP Cells Shown in [Figure 4](#fig4){ref-type="fig"}

  Gene Set                          NES[a](#tblfn1){ref-type="table-fn"}   p value   FDR[b](#tblfn2){ref-type="table-fn"}
  --------------------------------- -------------------------------------- --------- --------------------------------------
  Bile acid metabolism              2.32                                   \<0.001   \<0.001
  Coagulation                       2.25                                   \<0.001   \<0.001
  Xenobiotic metabolism             2.20                                   \<0.001   \<0.001
  Fatty acid metabolism             2.20                                   \<0.001   \<0.001
  Heme metabolism                   2.04                                   \<0.001   \<0.001
  Adipogenesis                      1.91                                   \<0.001   \<0.001
  Peroxisome                        1.90                                   \<0.001   \<0.001
  Interferon alpha response         1.90                                   \<0.001   \<0.001
  Oxidative phosphorylation         1.90                                   \<0.001   \<0.001
  Estrogen response late            1.89                                   \<0.001   \<0.001
  Angiogenesis                      1.72                                   0.002     0.003
  Cholesterol homeostasis           1.68                                   0.004     0.005
  Hypoxia                           1.61                                   \<0.001   0.010
  Interferon gamma response         1.60                                   \<0.001   0.009
  Reactive oxygen species pathway   1.59                                   0.013     0.010
  Estrogen response early           1.58                                   \<0.001   0.011
  Myogenesis                        1.57                                   0.002     0.012
  IL2 STAT5 signaling               1.54                                   \<0.001   0.013
  IL6 JAK STAT3 signaling           1.54                                   0.008     0.014
  Complement                        1.49                                   0.003     0.021
  MTORC1 signaling                  −1.50                                  0.005     0.012
  Unfolded protein response         −1.82                                  \<0.001   \<0.001
  G2M checkpoint                    −2.01                                  \<0.001   \<0.001
  E2F targets                       −2.02                                  \<0.001   \<0.001
  MYC targets V2                    −2.54                                  \<0.001   \<0.001
  MYC targets V1                    −2.64                                  \<0.001   \<0.001

Normalized enrichment score.

False discovery rate.
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